PDF, Patent Landscape Report on Atazanavir - WIPO

STAGE TWO CLINICAL SEARCHTo be more comprehensive, it was necessary to search for clinical names in the description(specification) section of the document as well, though this opens the possibility of addingsignificant “noise” to the collection. Unlike the rather targeted result that was obtained fromsearching titles, abstracts, claims or enhanced abstracts, searching the description fieldwith the clinical names returned a 6-7 fold higher number of invention families (eitherInpadoc or DWPI families), but this retrieval was likely to include a high fraction ofdocuments outside the desired scope. To diagnose the quality of the collection, theThemeScape map below shows the Stage-One documents and the new documents addedby the Stage-Two search mixed together. There are large regions in the map where veryfew inventions of the Stage-One collection are located (areas outlined in yellow). If weassume Stage-One is an indicator of higher relevance, that means the relevance in Stage-One-poor areas of the map is questionable. It is clear that the documents retrieved bysearching the description need to be reviewed to remove those that are not truly orientedtoward Atazanavir development. This is where use of either classification codes or otherfiltering methods becomes critical.Figure 7. Stage-Two Clinical Collection – Map shows collection improvement is needed13